tiprankstipranks
Advertisement
Advertisement
Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition
PremiumCompany AnnouncementsGyre Therapeutics Completes Cullgen Acquisition and Leadership Transition
18d ago
Gyre Therapeutics Files NDA in China for F351
Premium
Company Announcements
Gyre Therapeutics Files NDA in China for F351
2M ago
Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval
Premium
Ratings
Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval
2M ago
Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M
PremiumThe FlyGyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M
2M ago
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger
Premium
Company Announcements
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger
3M ago
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Premium
The Fly
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
3M ago
Gyre Therapeutics announces alignment with China’s CDE on hydronidone
PremiumThe FlyGyre Therapeutics announces alignment with China’s CDE on hydronidone
5M ago
Gyre Therapeutics Reports Strong Q3 2025 Results
Premium
Company Announcements
Gyre Therapeutics Reports Strong Q3 2025 Results
7M ago
Strategic Advancements and Financial Growth Drive Buy Rating for Gyre Therapeutics
Premium
Ratings
Strategic Advancements and Financial Growth Drive Buy Rating for Gyre Therapeutics
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100